Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial

被引：1

作者：

Eskander, Ramez ^{[1
]}

Sill, Michael ^{[2
]}

Beffa, Lindsey ^{[3
]}

Moore, Richard ^{[4
]}

Hope, Joanie ^{[5
]}

Musa, Fernanda ^{[5
]}

Mannel, Robert ^{[6
]}

Shahin, Mark ^{[7
]}

Cantuaria, Guilherme ^{[8
]}

Girda, Eugenia ^{[9
]}

Mathews, Cara ^{[10
]}

Kavecansky, Juraj ^{[11
]}

Leath, Charles ^{[12
]}

Gien, Lilian ^{[13
]}

Hinchcliff, Emily ^{[14
]}

Lele, Shashikant ^{[2
]}

Landrum, Lisa ^{[15
]}

Backes, Floor ^{[16
]}

O'Cearbhaill, Roisin ^{[17
]}

Liu, Rebecca ^{[18
]}

Hill, Emily ^{[19
]}

Thaker, Premal H. ^{[20
]}

John, Veena ^{[21
]}

Powell, Matthew ^{[20
]}

Aghajanian, Carol

机构：

[1] Univ Calif San Diego, La Jolla, CA 92093 USA

[2] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[3] Cleveland Clin, Cleveland, OH 44106 USA

[4] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[5] Pacific Canc Res Consortium NCORP, Seattle, WA USA

[6] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[7] Thomas Jefferson Univ, Willow Grove, PA USA

[8] Georgia NCI Community Oncol Res, Atlanta, GA USA

[9] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[10] Women & Infants Hosp Rhode Isl, Providence, RI USA

[11] Kaiser Permanente, Walnut Creek, CA USA

[12] Univ Alabama Birmingham, Birmingham, AL USA

[13] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[14] Northwestern Univ, Chicago, IL 60611 USA

[15] Indiana Univ, Indianapolis, IN 46204 USA

[16] Ohio State Univ, Columbus, OH 43210 USA

[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[18] Trinity Hlth IHA Med Grp, Michigan Canc Res Consortium NCORP, Ypsilanti, MI USA

[19] Univ Iowa, Iowa City, IA USA

[20] Washington Univ St Louis, St Louis, MO USA

[21] Northwell Hlth Canc Inst, Lake Success, NY USA

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

10.1016/j.ygyno.2024.07.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

02 [LBA]

引用

页码：S5 / S5

页数：1

共 38 条

[21] ABCB1 (MDR1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy (vol 14, pg 5594, 2008)
Johnatty, S. E.
Beesley, J.
Paul, J.
Fereday, S.
Spurdle, A. B.
Webb, P. M.
CLINICAL CANCER RESEARCH, 2012, 18 (01) : 319 - 320
[22] Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Mccourt, Carolyn
Ronzino, Graziana
Shahin, Mark S.
Kristeleit, Rebecca
Willmott, Lyndsay
Zub, Oleksandr
Barlin, Joyce N.
Gilbert, Lucy
Cloven, Noelle
Bjorge, Line
Black, Destin
Wymenga, Machteld
Sharma, Sudarshan
Gold, Michael A.
Landrum, Lisa
Mathews, Cara
Antony, Grace
Stevens, Shadi
Powell, Matthew A.
Mirza, Mansoor Raza
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A18 - A20
[23] Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with dostarlimab plus chemotherapy in the RUBY trial.
Mirza, Mansoor Raza
Sharma, Sudarshan
Roed, Henrik
Landrum, Lisa M.
Gilbert, Lucy
Gold, Michael A.
Novak, Zoltan
Edelson, Mitchell
Meirovitz, Mihai
Diaz, John Paul
Huygh, Greet
Buscema, Joseph
Pothuri, Bhavana
Eshed, Helen Dinkelspiel
Coleman, Robert L.
Slomovitz, Brian M.
Kostadinov, Rumen
Stevens, Shadi
Ronzino, Graziana
Powell, Matthew A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] Angiotensin-converting enzyme inhibitor prescription is associated with decreased progression-free survival (PFS) and overall survival (OS) in patients with lung cancers treated with PD-1/PD-L1 immune checkpoint blockers.
Medjebar, Soleine
Richard, Corentin
Fumet, Jean-David
Malo, Julie
Elkrief, Arielle
Blais, Normand
Tehfe, Mustapha
Florescu, Marie
Boidot, Romain
Truntzer, Caroline
Routy, Bertrand
Ghiringhelli, Francois
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[25] Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
Dora, David
Ligeti, Balazs
Kovacs, Tamas
Revisnyei, Peter
Galffy, Gabriella
Dulka, Edit
Krizsan, Daniel
Kalcsevszki, Regina
Megyesfalvi, Zsolt
Dome, Balazs
Weiss, Glen J.
Lohinai, Zoltan
ONCOIMMUNOLOGY, 2023, 12 (01):
[26] Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Liu, Stephen, V
Reck, Martin
Mansfield, Aaron S.
Mok, Tony
Scherpereel, Arnaud
Reinmuth, Niels
Garassino, Marina Chiara
Carpeno, Javier De Castro
Califano, Raffaele
Nishio, Makoto
Orlandi, Francisco
Alatorre-Alexander, Jorge
Leal, Ticiana
Cheng, Ying
Lee, Jong-Seok
Lam, Sivuonthanh
McCleland, Mark
Deng, Yu
Phan, See
Horn, Leora
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06) : 619 - +
[27] Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a firstline treatment for endometrial cancer: Overall survival and additional secondary efficacy en-dpoints by mismatch repair status in the DUO-E/GOG-3041/ ENGOT-EN10 Trial
Baurain, Jean-Francois
Chon, Hye Sook
Pepin, Jessica Thomes
Sundborg, Michael
Gold, Michael
Kim, Byoung-Gie
Blank, Stephanie
Liu, Ji-Hong
McCollum, Michael
Mori, Masahiko
Jonuskiene, Goda
Moore, Kathleen
Novak, Zoltan
Ramos Guette, Pedro Luis
Joseph de Padua, Charles Andree
Martin, Marta Gil
Kowgier, Matthew
del Rosario, Paula Michelle
Westin, Shannon
Van Nieuwenhuysen, Els
GYNECOLOGIC ONCOLOGY, 2024, 190 : S62 - S63
[28] One-year progression-free survival in lung cancer patients treated with immune checkpoint inhibitors is significantly associated with a novel immunomodulatory signature but not PD-L1 staining
Ranganath, Harsha
Jain, Amit
Smith, Justin
Ryder, Julie
Chaudry, Amina
Miller, Emily
Hare, Felicia
Valasareddy, Poojitha
Seitz, Rob
Hout, David
Schweitzer, Brock
Nielsen, Tyler
Mullins, Janice
Vidal, Gregory
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[29] The effect of anemia on the progression-free survival in epithelial ovarian cancer (stage II-IV) patients treated with paclitaxel-carboplatin combination therapy: a retrospective analysis of the JGOG3016 trial of the Japanese Gynecologic Oncology Group (JGOG3016-A)
Sugiyama, T.
Kumagai, S.
Shouji, T.
Michimae, H.
Katsumata, N.
Tsuda, H.
Aoki, D.
Terauchi, F.
Jobo, T.
Yasuda, M.
EJC SUPPLEMENTS, 2009, 7 (02): : 456 - 456
[30] IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin plus nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC
West, Howard L.
McCleod, Michael
Hussein, Maen
Morabito, Alessandro
Rittmeyer, Achim
Conter, Henry J.
Kopp, Hans-Georg
Daniel, Davey
McCune, Steven
Mekhail, Tarek
Zer, Alona
Reinmuth, Niels
Sadiq, Ahad
Archer, Venice
Lohmann, Tania Ochi
Jessop, Helen
Wang, Lijia
Kowanetz, Marcin
Sandler, Alan
Cappuzzo, Federico
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 →